At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
MLS-101 (Part I) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
In Brief
A Phase 2 clinical trial evaluating MLS-101 (Part I), Placebo (Part I), and 2 other interventions for Hypertension, Renal. Completed, enrolled 200 participants across 44 sites.
Detailed Summary
A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Renal
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedAug 2021
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedAug 12, 2021
Enrollment StartJul 1, 2021
Primary CompletionSep 7, 2022
Study CompletionOct 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.9 years ago
Interventions
MLS-101 (Part I)drug
MLS-101 tablet(s) by mouth once or twice daily.
Placebo (Part I)other
Placebo tablet(s) by mouth once or twice daily.
Placebo (Part II)other
Placebo tablet(s) by mouth once daily.
MLS-101 (Part II)drug
MLS-101 tablet(s) by mouth once daily.